EWTX
Edgewise Therapeutics Inc. · NASDAQ
- Market cap
- $5.03B
Edgewise Therapeutics Inc. (EWTX) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 9 wire items for EWTX, including 4 press releases and news items, 2 SEC filings and 1 earnings update. The most recent was published Nov 10, 2026.
EWTX rankings
Financial highlights
Full financials- Net income, TTM
- $1.01B
- Free cash flow, TTM
- -$202.28M
- Cash
- $68.68M
For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks56+125%
2026-05-242026-11-15
Mix1690d
- Other8(50%)
- Earnings2(13%)
- Insider2(13%)
- SEC Filings2(13%)
- Analyst1(6%)
- 13D/G1(6%)
Activity · 52 weeks9657 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- INSIDERChief Financial Officer Nofi Michael converted options into 10,937 shares and sold $201,787 worth of shares (4,442 units at $45.43) (SEC Form 4) to cover withholding tax4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- PR/C O R R E C T I O N - Edgewise Therapeutics/In the news release, Edgewise Therapeutics to Participate in Upcoming Investor Conferences, issued 09-Nov-2026 by Edgewise Therapeutics over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional details at the end:Edgewise Therapeutics to Participate in Upcoming Investor Conference BOULDER, Colo., Nov. 9, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (NASDAQ:EWTX), a leading clinical-stage cardiovascular biopharmaceutical company, today announced that management will participate in the following investor conference: Guggenheim 3rd Annual Healthcare In
- PREdgewise Therapeutics to Participate in Upcoming Investor ConferencesBOULDER, Colo., Nov. 9, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (NASDAQ:EWTX), a leading clinical-stage cardiovascular biopharmaceutical company, today announced that management will participate in the following investor conferences: Guggenheim 3rd Annual Healthcare Innovation ConferenceFireside chat: Tuesday, November 10, 2026 at 8:00 am ET2026 Truist Biopharma SymposiumFireside chat: Thursday, November 12, 2026 at 10:30 am ETThe webcasts can be found on the Edgewise Events & Presentations page and will be accessible for replay, for a limited time, following the conference. It is recommended that users connect to the
- 13D/GAmendment: SEC Form SCHEDULE 13G/A filed by Edgewise Therapeutics Inc.SCHEDULE 13G/A - Edgewise Therapeutics, Inc. (0001710072) (Subject)
- PREdgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3 Protocol Features Tolerability-Based Dose Escalation Without Safety Echo Monitoring– Following the End-of-Phase 2 meeting, Edgewise has submitted the STRATUS-HCM Phase 3 protocol with dose escalation guided by investigator assessment of tolerability –– STRATUS-HCM includes two independent placebo-controlled studies of symptomatic obstructive and nonobstructive HCM populations under a single master protocol, with peak VO₂ as the primary endpoint –– STRATUS-HCM on track to start in the fourth quarter of 2026 –BOULDER, Colo., Nov. 5, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (NASDAQ:EWTX), a leading clinical-stage cardiovascular biopharmaceutical company, today announced favorable feedback from its End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA)
- SECSEC Form 10-Q filed by Edgewise Therapeutics Inc.10-Q - Edgewise Therapeutics, Inc. (0001710072) (Filer)
- SECEdgewise Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Edgewise Therapeutics, Inc. (0001710072) (Filer)
- PREdgewise Therapeutics Reports Third Quarter 2026 Financial Results– Published the differentiated mechanism of action of EDG-7500 that targets the regulatory light chain –– Phase 3 trial for EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) on track to initiate by year-end 2026 –– Dosed first patient in Phase 2 EQUINOX-HFpEF trial of EDG-15400 in heart failure with preserved ejection fraction (HFpEF) –BOULDER, Colo., Nov. 4, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (NASDAQ:EWTX), a leading clinical-stage cardiovascular biopharmaceutical company, today reported financial results for the third quarter of 2026 and recent business highlights. "Our third quarte
- PREdgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing RulesBOULDER, Colo., Nov. 2, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (NASDAQ:EWTX), a leading clinical-stage cardiovascular biopharmaceutical company, today announced that on October 30, 2026, Edgewise granted inducement stock options to purchase a total of 17,250 shares of Edgewise's common stock and awards of inducement restricted stock units (each, an "RSU award") covering a total of 8,626 shares of Edgewise's common stock to 2 new non-executive employees in connection with the commencement of their employment, pursuant to Edgewise's 2024 Inducement Equity Incentive Plan (the "Inducement Plan").
- ANALYSTWilliam Blair initiated coverage on Edgewise TherapeuticsWilliam Blair initiated coverage of Edgewise Therapeutics with a rating of Outperform
- PREdgewise Therapeutics Doses First Patient in Phase 2 EQUINOX-HFpEF Trial of EDG-15400– Phase 2 trial evaluating EDG-15400 in adults with symptomatic HFpEF with a LVEF of at least 50% –– EQUINOX-HFpEF trial design and EDG-15400 Phase 1 first-in-human data to be presented at HFSA 2026 –BOULDER, Colo., Oct. 8, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (NASDAQ:EWTX), a leading clinical-stage biopharmaceutical company focused on cardiometabolic diseases, today announced the dosing of the first patient in EQUINOX-HFpEF, a Phase 2 clinical trial evaluating EDG-15400 in adults with symptomatic heart failure with preserved ejection fraction (HFpEF) who have a left ventricular ejection fraction (LVEF) of at least 50%.EDG-15400 is an investigational, oral, selective cardiac sarc
- INSIDERDirector Fox Jonathan C was granted 308 shares, increasing direct ownership by 1% to 25,141 units (SEC Form 4)4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- PREdgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing RulesBOULDER, Colo., Oct. 1, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (NASDAQ:EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today announced that on September 30, 2026, Edgewise granted inducement stock options to purchase a total of 7,500 shares of Edgewise's common stock and awards of inducement restricted stock units (each, an "RSU award") covering a total of 3,751 shares of Edgewise's common stock to 3 new non-executive employees in connection with the commencement of their employment, pursuant to Edgewise's 2024 Inducement Equity Incentive Plan (the "Inducement Plan"). Each inducement stock option has an ex
- PREdgewise Therapeutics Unveils the Differentiated Mechanism of Action (MoA) of its Cardiac Sarcomere Modulator EDG-7500- The MoA that targets the Regulatory Light Chain (RLC) has shown in preclinical models to improve cardiac relaxation while preserving systolic function and cardiac reserve -- Company to host webcast to discuss these findings today at 8:30 a.m. Eastern Time -BOULDER, Colo., Sept. 22, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (NASDAQ:EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today announced that it will host an investor conference call to discuss the preclinical pharmacologic profile of EDG-7500, a first-in-class cardiac sarcomere modulator targeting the RLC. Data will be provided supporting EDG-7500's ability to improve cardiac relax
- PREdgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing RulesBOULDER, Colo., Sept. 2, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (NASDAQ:EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today announced that on August 31, 2026, Edgewise granted inducement stock options to purchase a total of 21,000 shares of Edgewise's common stock and awards of inducement restricted stock units (each, an "RSU award") covering a total of 10,501 shares of Edgewise's common stock to 4 new non-executive employees in connection with the commencement of their employment, pursuant to Edgewise's 2024 Inducement Equity Incentive Plan (the "Inducement Plan").
- PREdgewise Therapeutics Announces Upcoming Late-Breaking Science Presentation at the European Society of Cardiology (ESC) Congress 2026– Presentation highlights positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) –BOULDER, Colo., Aug. 24, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (NASDAQ:EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today announced that the CIRRUS-HCM abstract was selected for a late-breaking science presentation at the European Society of Cardiology (ESC) Congress, taking place August 28-31 in Munich, Germany. EDG-7500 is a novel, oral, selective cardiac sarcomere modulator designed to slow early contraction and improve cardiac relaxation in symptomatic HCM while
- INSIDERAmendment: SEC Form 4 filed by Chief Financial Officer Nofi Michael4/A - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by CMO Donovan Joanne M.4/A - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by Chief Scientific Officer Russell Alan J4/A - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by General Counsel Moore John R4/A - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by Chief Business Officer Derakhshan Behrad4/A - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Nofi Michael4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- INSIDERGeneral Counsel Moore John R converted options into 12,499 shares and sold $219,823 worth of shares (5,016 units at $43.82), increasing direct ownership by 73% to 17,697 units (SEC Form 4) (for tax liability)4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- INSIDERCMO Donovan Joanne M. converted options into 12,812 shares and sold $412,703 worth of shares (9,441 units at $43.71) as part of a pre-agreed trading plan, increasing direct ownership by 64% to 8,625 units (SEC Form 4) (for tax liability)4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- INSIDERChief Scientific Officer Russell Alan J converted options into 12,812 shares and sold $258,042 worth of shares (5,901 units at $43.73), increasing direct ownership by 28% to 31,466 units (SEC Form 4) to satisfy withholding obligation4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
EWTX FAQ
10 questionsWhat does Edgewise Therapeutics Inc. do?
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. It offers a precision medicine muscle platform that generates programs to address various muscle disorders, such as Duchenne, Becker, and limb girdle muscular dystrophies. The company develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was founded in 2017 and is headquartered in Boulder, Colorado.What is the latest news on EWTX?
In the last 30 days Quantisnow tracked 9 wire items for EWTX: 4 press releases and news items, 2 SEC filings, 1 earnings update and 1 13D/G filing. The most recent was published on November 10, 2026.Is EWTX profitable?
Yes. Edgewise Therapeutics Inc. earned $1.01B in net income for the twelve months ended Sep 30, 2026.How much cash and debt does EWTX have?
Edgewise Therapeutics Inc. reported $68.68M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does EWTX stock trade?
Edgewise Therapeutics Inc. (EWTX) is listed on NASDAQ.What sector and industry is EWTX in?
Edgewise Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Edgewise Therapeutics Inc. go public?
Edgewise Therapeutics Inc. (EWTX) completed its IPO in 2021.What are analysts saying about EWTX?
Across the last 8 analyst actions on Edgewise Therapeutics Inc., there were 0 upgrades and 1 downgrade. The most recent action was from William Blair: Outperform on 2026-10-16. Recent price targets range from $14.00 to $51.00.What companies are similar to EWTX?
Notable peers in the same industry include MRK (Merck & Company Inc.), NVO (Novo Nordisk A/S), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABT (Abbott Laboratories). Compare EWTX side-by-side with any of them on Quantisnow.How can I track EWTX on Quantisnow?
Quantisnow aggregates Edgewise Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow EWTX to receive live email and push alerts on every new disclosure.